TruTechnologies Unveils New Brand Identity as It Advances Real-Time Clinical Trial Innovation TruTechnologies, a clinical trial software company specializing in real-time visibility into trial execution at the point of care, has introduced a refreshed corporate brand identity alongside the launch…
Kairos Pharma Reports Encouraging Phase 1 Safety Results for ENV-105 Combined with Osimertinib in EGFR-Mutated Lung Cancer Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company focused on developing therapies to overcome drug resistance in cancer, has announced encouraging interim safety results…
Incyte Presents Positive Phase 1/2 Data for Latarcibart in Von Willebrand Disease, Supporting Ongoing Phase 3 Development Incyte has announced comprehensive safety and efficacy results from its Phase 1/2 multidose clinical study evaluating VGA039 (latarcibart), an investigational monoclonal antibody designed…
Meridian Bioscience Receives Health Canada Approval for Alethia® CMV Assay, Expanding Molecular Diagnostics Portfolio Meridian Bioscience, Inc., a global provider of diagnostic testing solutions and life science raw materials, has announced that Health Canada has granted a medical device license…
Ionis and Biogen Report Positive Phase 2 Results for Diranersen in Early Alzheimer’s Disease, Supporting Advancement to Phase 3 Ionis Pharmaceuticals, Inc. has announced that its long-standing collaboration partner, Biogen, presented new data from the Phase 2 CELIA clinical trial…
CEL-SCI Launches Global Confirmatory Registration Study of Multikine® for Newly Diagnosed Head and Neck Cancer CEL-SCI Corporation has announced the initiation of its global Confirmatory Registration Study evaluating Multikine® (Leukocyte Interleukin, Injection) as a neoadjuvant immunotherapy for patients with newly…
Anthem to Cover C2N Diagnostics’ PrecivityAD2® Blood Test, Expanding Access to Alzheimer’s Disease Diagnostics Beginning October 2026 C2N Diagnostics, LLC, a specialty diagnostics company focused on advancing precision medicine through innovative diagnostic technologies, has announced a significant milestone in Alzheimer’s…
LEO Pharma Reports Positive Phase 2 TRAPEDS-1 Results for Tralokinumab in Children with Moderate-to-Severe Atopic Dermatitis LEO Pharma A/S, a global company specializing in medical dermatology, has announced positive topline results from its Phase 2 TRAPEDS-1 clinical trial, which evaluated…
Retham Technologies Launches Next-Generation Cryoplatelets to Improve Platelet Research and Laboratory Testing Retham Technologies, Inc. has announced the commercial launch of Retham Cryoplatelets™, a next-generation functional platelet product developed to address one of the most persistent challenges in biomedical research—the…
Randomized Trial Highlights Ketogenic Diet Benefits in Psychotic Disorders A new clinical study published in Schizophrenia Bulletin has provided encouraging evidence that a ketogenic diet may offer meaningful benefits for individuals living with serious mental illnesses such as schizophrenia-spectrum disorders…
Niagen Bioscience Launches NB4168 Pharmaceutical Program Targeting Rare Genetic Diseases and Accelerated Aging Niagen Bioscience expands its leadership in NAD+ science into pharmaceutical development with NB4168, an investigational oral therapy designed for Ataxia Telangiectasia and other DNA repair disorders. Niagen…
Agilent Expands Altura HPLC Portfolio with New SEC and PLRP-S Columns to Advance Biopharmaceutical Analysis Agilent Technologies Inc. has expanded its Altura high-performance liquid chromatography (HPLC) column portfolio with the launch of Altura Size Exclusion Chromatography (SEC) and Altura PLRP-S…